Page 1 | Search Results | Hematology, ASH Education Program

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Is there a role for low-dose DOACs as prophylaxis?

Alexander T. Cohen, Beverley J. Hunt

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 187–193.

https://doi.org/10.1182/hematology.2019000026

Published: 2019

Journal Articles

Direct oral anticoagulant monitoring: what laboratory tests are available to guide us?

Ravi Sarode

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 194–197.

https://doi.org/10.1182/hematology.2019000027

Published: 2019

Journal Articles

What we have learned about direct oral anticoagulant reversal

Deborah M. Siegal

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 198–203.

https://doi.org/10.1182/hematology.2019000072

Published: 2019

Journal Articles

Anticoagulating patients with high-risk acquired thrombophilias

Leslie Skeith

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 439–449.

https://doi.org/10.1182/asheducation-2018.1.439

Published: 2018

Journal Articles

Management of thrombosis in children and neonates: practical use of anticoagulants in children

Paul Monagle, Fiona Newall

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 399–404.

https://doi.org/10.1182/asheducation-2018.1.399

Published: 2018

Journal Articles

Elite athletes and anticoagulant therapy: an intermittent dosing strategy

Stephan Moll, Joshua N. Berkowitz, Christopher W. Miars

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 412–417.

https://doi.org/10.1182/asheducation-2018.1.412

Published: 2018

Journal Articles

Role of the anticoagulant monitoring service in 2018: beyond warfarin

Nathan P. Clark

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 348–352.

https://doi.org/10.1182/asheducation-2018.1.348

Published: 2018

Journal Articles

Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions

Sara R. Vazquez

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 339–347.

https://doi.org/10.1182/asheducation-2018.1.339

Published: 2018

Journal Articles

Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?

Ingrid Pabinger, Julia Riedl

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 136–143.

https://doi.org/10.1182/asheducation-2017.1.136

Published: 2017

Journal Articles

Risk stratification and management of acute pulmonary embolism

Cecilia Becattini, Giancarlo Agnelli

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 404–412.

https://doi.org/10.1182/asheducation-2016.1.404

Published: 2016

Journal Articles

Reversal of direct oral anticoagulants: a practical approach

Andrew W. Shih, Mark A. Crowther

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 612–619.

https://doi.org/10.1182/asheducation-2016.1.612

Published: 2016

Journal Articles

Monitoring and reversal of direct oral anticoagulants

Adam Cuker, Deborah Siegal

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 117–124.

https://doi.org/10.1182/asheducation.V2015.1.117.3916182

Published: 2015

Journal Articles

Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations

Nick van Es, Harry R. Büller

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 125–131.

https://doi.org/10.1182/asheducation-2015.1.125

Published: 2015

Journal Articles

The antiphospholipid syndrome: still an enigma

Shruti Chaturvedi, Keith R. McCrae

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 53–60.

https://doi.org/10.1182/asheducation-2015.1.53

Published: 2015

Journal Articles

Reversing targeted oral anticoagulants

Maureane Hoffman, Dougald M. Monroe

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 518–523.

https://doi.org/10.1182/asheducation-2014.1.518

Published: 2014

Journal Articles

Pros and cons of new oral anticoagulants

Kenneth A. Bauer

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 464–470.

https://doi.org/10.1182/asheducation-2013.1.464

Published: 2013

NARROW

Is there a role for low-dose DOACs as prophylaxis?

Direct oral anticoagulant monitoring: what laboratory tests are available to guide us?

What we have learned about direct oral anticoagulant reversal

Anticoagulating patients with high-risk acquired thrombophilias

Management of thrombosis in children and neonates: practical use of anticoagulants in children

Elite athletes and anticoagulant therapy: an intermittent dosing strategy

Role of the anticoagulant monitoring service in 2018: beyond warfarin

Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions

Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?

Risk stratification and management of acute pulmonary embolism

Reversal of direct oral anticoagulants: a practical approach

Monitoring and reversal of direct oral anticoagulants

Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations

The antiphospholipid syndrome: still an enigma

Reversing targeted oral anticoagulants

Pros and cons of new oral anticoagulants

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only